Tim Wright, Editor, Contract Pharma11.13.18
Cambrex is an innovative life sciences company that provides pharmaceutical products, expertise and technologies that accelerate small molecule therapeutics into markets across the world.
The company has a network of development and manufacturing plants across Europe and North America. With Cambrex’s recent acquisition of Halo Pharma, the company now offers formulation development and finished dose clinical and commercial manufacturing services. Cambrex’s acquisition of Halo creates a leading small molecule contract development and manufacturing organization (CDMO) with a broad range of capabilities and a robust customer base.
Shawn Cavanagh is Cambrex's executive vice president and chief operating officer.
Its team of more than 1,650 experts offer an end-to-end partnership for the research, development and manufacture of small molecule at every stage of the lifecycle, and handle classical and advanced chemistry, enzymatic biotransformations, high potency APIs, high
The company has a network of development and manufacturing plants across Europe and North America. With Cambrex’s recent acquisition of Halo Pharma, the company now offers formulation development and finished dose clinical and commercial manufacturing services. Cambrex’s acquisition of Halo creates a leading small molecule contract development and manufacturing organization (CDMO) with a broad range of capabilities and a robust customer base.
Shawn Cavanagh is Cambrex's executive vice president and chief operating officer.
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
